NCT06905197View on ClinicalTrials.gov

A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 13, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2028

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

DZD6008

Daily dose of DZD6008

Trial Locations (5)

2050

NOT_YET_RECRUITING

Chris O'Brien Lifehouse, Camperdown

2148

ACTIVE_NOT_RECRUITING

Blacktown Hospital, Blacktown

10016

RECRUITING

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York

10032

RECRUITING

Herbert Irving Comprehensive Cancer Center, New York

22031

ACTIVE_NOT_RECRUITING

Virginia Cancer Specialist (NEXT Oncology-Virginia), Fairfax

Sponsors
All Listed Sponsors
lead

Dizal Pharmaceuticals

INDUSTRY